1. Home
  2. DKL vs SLNO Comparison

DKL vs SLNO Comparison

Compare DKL & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DKL

Delek Logistics Partners

HOLD

Current Price

$51.51

Market Cap

2.7B

Sector

Energy

ML Signal

HOLD

Logo Soleno Therapeutics Inc.

SLNO

Soleno Therapeutics Inc.

HOLD

Current Price

$52.95

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DKL
SLNO
Founded
2012
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Natural Gas Distribution
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.3B
IPO Year
2012
2014

Fundamental Metrics

Financial Performance
Metric
DKL
SLNO
Price
$51.51
$52.95
Analyst Decision
Hold
Buy
Analyst Count
3
9
Target Price
$53.67
$83.00
AVG Volume (30 Days)
48.7K
2.5M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
8.52%
N/A
EPS Growth
N/A
108.90
EPS
N/A
0.59
Revenue
N/A
$1,450,788.00
Revenue This Year
$2.73
$150.46
Revenue Next Year
$6.82
$50.37
P/E Ratio
$17.62
$135.77
Revenue Growth
N/A
138.82
52 Week Low
$38.02
$29.43
52 Week High
$55.89
$89.12

Technical Indicators

Market Signals
Indicator
DKL
SLNO
Relative Strength Index (RSI) 49.76 77.35
Support Level $50.17 $48.91
Resistance Level $54.97 $55.47
Average True Range (ATR) 1.63 0.08
MACD 0.10 -0.57
Stochastic Oscillator 39.92 96.43

Price Performance

Historical Comparison
DKL
SLNO

About DKL Delek Logistics Partners

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About SLNO Soleno Therapeutics Inc.

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Share on Social Networks: